Asian press release distribution

Press Releases for Monday, April 27, 2020

Blockchain Startup Domineum.io Generates $5 Million for African Govts within 11 Months 22:20 HKT/SGT

中國鼎益豐情況明朗化 16:35 HKT/SGT

Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine 16:26 HKT/SGT

英国房地产数字货币Breezecoin（BRZE）上线 Bithumb Global 交易所 16:02 HKT/SGT

Mitsubishi Motors Starts Production of Face Shields to Help Prevent the Spread of COVID-19 Infections 16:01 HKT/SGT

英國房地產數字貨幣Breezecoin（BRZE）上線 Bithumb Global 交易所 16:01 HKT/SGT

三菱自動車、フェイスシールド生産、新型コロナウイルス感染拡大防止への支援 16:00 HKT/SGT

三菱日立パワーシステムズ、2019年の排煙脱硫装置（FGD）世界市場でシェア1位を獲得 16:00 HKT/SGT

トヨタモビリティ東京株式会社、江戸川区に新型コロナウィルス感染者移送用の車両を提供 16:00 HKT/SGT

UK Real Estate Cryptocurrency Breezecoin (BRZE) Lists on Bithumb Global 16:00 HKT/SGT

トヨタと中国第一汽車集団有限公司、中国における持続的成長に向け、合弁会社の管理体制を再編 14:30 HKT/SGT

TOYOTA、クラウンに65周年を記念した特別仕様車を設定 13:30 HKT/SGT

Toyota and FAW Restructure their Joint Company's Management Systems with the Aim of Sustainable Growth in China 13:06 HKT/SGT

MHPS the Global Market Share Leader in 2019 for Flue Gas Desulfurization Systems 12:41 HKT/SGT

中国透云举行盛大动土奠基仪式打造全球首座莱茵衣藻工厂 10:39 HKT/SGT

中國透雲舉行盛大動土奠基儀式打造全球首座萊茵衣藻工廠 10:38 HKT/SGT

华领医药宣布Dorzagliatin与恩格列净（一种SGLT-2抑制剂）联合用药临床研究的成功结果 09:53 HKT/SGT

華領醫藥宣佈Dorzagliatin與恩格列淨（一種SGLT-2抑制劑）聯合用藥臨床研究的成功結果 09:51 HKT/SGT

Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) 09:50 HKT/SGT

Fujitsu Releases Notice Regarding the Postponement of FY 2019 Full-Year Financial Results Announcement 08:07 HKT/SGT

Retarus Presents Free Anti-Phishing Guide 08:00 HKT/SGT

Bankcoin Reserve (BCR) Fintech Platform Partners with HomiEx 06:00 HKT/SGT

ACN Search:

CITIC Telecom CPC Becomes New VMware Cloud Service Provider Pinnacle Tier Partner in the Broadcom Advantage Partner Program


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575